Pathogenesis of the acute coronary syndromes and therapeutic implications. 2002

L Badimon, and J J Badimon, and G Vilahur, and E Segalés, and V Llorente
Cardiovascular Research Center, ICCC-CSIC, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. lbmucv@cid.csic.es

Atherosclerosis is characterized by the thickening and obstruction of the arterial lumen and thrombosis associated with vulnerable disrupted plaques seems to be responsible for the accelerated process of clinical syndrome presentation. Strategies to promote plaque stabilization and reduce thrombus burden have been one of the major targets of recent times. Modification of diet and lifestyle has important benefit in reducing coronary risk. Several pharmacological strategies for reducing cardiovascular morbidity and mortality have demonstrated effectiveness. Statins and angiotensin converting enzyme, fibrinolytics, inhibitors of the intrinsic coagulation cascade and anti-platelet agents have been developed to reduce the impact of atherosclerosis and inhibit thrombogenesis.

UI MeSH Term Description Entries
D009203 Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION). Cardiovascular Stroke,Heart Attack,Myocardial Infarct,Cardiovascular Strokes,Heart Attacks,Infarct, Myocardial,Infarction, Myocardial,Infarctions, Myocardial,Infarcts, Myocardial,Myocardial Infarctions,Myocardial Infarcts,Stroke, Cardiovascular,Strokes, Cardiovascular
D003327 Coronary Disease An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels. Coronary Heart Disease,Coronary Diseases,Coronary Heart Diseases,Disease, Coronary,Disease, Coronary Heart,Diseases, Coronary,Diseases, Coronary Heart,Heart Disease, Coronary,Heart Diseases, Coronary
D005343 Fibrinolytic Agents Fibrinolysin or agents that convert plasminogen to FIBRINOLYSIN. Antithrombic Drug,Antithrombotic Agent,Antithrombotic Agents,Fibrinolytic Agent,Fibrinolytic Drug,Thrombolytic Agent,Thrombolytic Agents,Thrombolytic Drug,Antithrombic Drugs,Fibrinolytic Drugs,Thrombolytic Drugs,Agent, Antithrombotic,Agent, Fibrinolytic,Agent, Thrombolytic,Agents, Antithrombotic,Drug, Antithrombic,Drug, Fibrinolytic,Drug, Thrombolytic,Drugs, Antithrombic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000925 Anticoagulants Agents that prevent BLOOD CLOTTING. Anticoagulant Agent,Anticoagulant Drug,Anticoagulant,Anticoagulant Agents,Anticoagulant Drugs,Anticoagulation Agents,Indirect Thrombin Inhibitors,Agent, Anticoagulant,Agents, Anticoagulant,Agents, Anticoagulation,Drug, Anticoagulant,Drugs, Anticoagulant,Inhibitors, Indirect Thrombin,Thrombin Inhibitors, Indirect

Related Publications

L Badimon, and J J Badimon, and G Vilahur, and E Segalés, and V Llorente
January 2013, Journal of the American College of Cardiology,
L Badimon, and J J Badimon, and G Vilahur, and E Segalés, and V Llorente
September 1998, Nihon rinsho. Japanese journal of clinical medicine,
L Badimon, and J J Badimon, and G Vilahur, and E Segalés, and V Llorente
September 2001, Clinica chimica acta; international journal of clinical chemistry,
L Badimon, and J J Badimon, and G Vilahur, and E Segalés, and V Llorente
April 2004, Revista clinica espanola,
L Badimon, and J J Badimon, and G Vilahur, and E Segalés, and V Llorente
January 1999, Scandinavian journal of clinical and laboratory investigation. Supplementum,
L Badimon, and J J Badimon, and G Vilahur, and E Segalés, and V Llorente
January 2005, Wiadomosci lekarskie (Warsaw, Poland : 1960),
L Badimon, and J J Badimon, and G Vilahur, and E Segalés, and V Llorente
August 1954, Technical bulletin. United States. Veterans Administration,
L Badimon, and J J Badimon, and G Vilahur, and E Segalés, and V Llorente
January 2001, Cardiovascular toxicology,
L Badimon, and J J Badimon, and G Vilahur, and E Segalés, and V Llorente
May 2005, Italian heart journal : official journal of the Italian Federation of Cardiology,
L Badimon, and J J Badimon, and G Vilahur, and E Segalés, and V Llorente
January 1999, Indian journal of clinical biochemistry : IJCB,
Copied contents to your clipboard!